US appeal denied in Czech blood plasma saga
The Prague-based dispute spans almost three decades following enforcement action in seven jurisdictions (Credit: iStock/COffe72)
A Liechtenstein company has failed in its latest bid to enforce a US$400 million award against the Czech Republic in the US courts, as its founder pursues a related investment treaty claim worth US$2.5 billion.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.
Subscribe now